日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial

宫颈鳞状细胞癌新辅助放化疗前免疫检查点阻断治疗（GINECO 机会窗口 COLIBRI 研究）：一项 II 期试验

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-67646-z
Ray-Coquard, Isabelle; Kaminsky-Forrett, Marie-Christine; Ohkuma, Ryotaro; de Montfort, Aymeric; Joly, Florence; Treilleux, Isabelle; Ghamry-Barrin, Sarah; Bello-Roufai, Diana; Saintigny, Pierre; Angelergues, Antoine; Michon, Lucas; Hardy-Bessard, Anne-Claire; Attignon, Valéry; Auclair, Jessie; Chemin, Gabriel; Lainé, Alexandra; Péré, Hélène; Veyer, David; Savoye, Aude-Marie; Berthet, Justine; Caux, Christophe; Lecuru, Fabrice; Dubois, Bertrand; Bétrian, Sarah
肿瘤
肿瘤免疫
COL
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma.

循环肿瘤DNA能够很好地预测晚期胃食管腺癌患者接受化疗联合免疫检查点抑制剂治疗的疗效

期刊:Commun Med (Lond)
影响因子:
doi:10.1038/s43856-025-00867-x
Tougeron David, Louvet Christophe, Desramé Jérôme, Evesque Ludovic, Angelergues Antoine, Carnot Aurélien, Breysacher Gilles, Zaanan Aziz, Etchepare Nicolas, Mabro May, Kaluzinski Laure, Petorin Caroline, Chibaudel Benoist, Aparicio Thomas, Bodere Anaïs, Rinaldi Yves, Le Malicot Karine, Emile Jean-François, Lepage Côme, Baures Aurélia, Djamai Hanane, Taly Valérie, Laurent-Puig Pierre
肿瘤
发表日期：2025
文献求助 收藏

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial

FOLFIRI联合度伐利尤单抗（加或不加曲美利木单抗）二线治疗晚期胃癌或胃食管交界处腺癌：PRODIGE 59-FFCD 1707-DURIGAST随机临床试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2024.0207
Tougeron, David; Dahan, Laetitia; Evesque, Ludovic; Le Malicot, Karine; El Hajbi, Farid; Aparicio, Thomas; Bouché, Olivier; Bonichon Lamichhane, Nathalie; Chibaudel, Benoist; Angelergues, Antoine; Bodere, Anaïs; Phelip, Jean-Marc; Mabro, May; Kaluzinski, Laure; Petorin, Caroline; Breysacher, Gilles; Rinaldi, Yves; Zaanan, Aziz; Smith, Denis; Gouttebel, Marie-Claude; Perret, Clément; Etchepare, Nicolas; Emile, Jean-François; Sanfourche, Ivan; Di Fiore, Frédéric; Lepage, Côme; Artru, Pascal; Louvet, Christophe
胃癌
肿瘤
肿瘤免疫
PROD
IGE
发表日期：2024
文献求助 收藏

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

新辅助和辅助帕博利珠单抗治疗晚期高级别浆液性癌：随机 II 期 NeoPembrOV 临床试验

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-024-46999-x
Ray-Coquard, Isabelle L; Savoye, Aude-Marie; Schiffler, Camille; Mouret-Reynier, Marie-Ange; Derbel, Olfa; Kalbacher, Elsa; LeHeurteur, Marianne; Martinez, Alejandra; Cornila, Corina; Martinez, Mathilde; Bengrine Lefevre, Leila; Priou, Frank; Cloarec, Nicolas; Venat, Laurence; Selle, Frédéric; Berton, Dominique; Collard, Olivier; Coquan, Elodie; Le Saux, Olivia; Treilleux, Isabelle; Gouerant, Sophie; Angelergues, Antoine; Joly, Florence; Tredan, Olivier
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer

TEDOVA：疫苗 OSE2101 +/- 帕博利珠单抗作为铂敏感复发性卵巢癌的维持治疗

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2024.2386922
Kabirian, Rayan; Tredan, Olivier; Marmé, Frederik; Paoletti, Xavier; Eberst, Lauriane; Lebreton, Coriolan; De La Motte Rouge, Thibault; Sabatier, Renaud; Angelergues, Antoine; Fabbro, Michel; Van Gorp, Toon; Mansi, Laura; Gladieff, Laurence; Kaczmarek, Emilie; Alexandre, Jérôme; Grellety, Thomas; Favier, Laure; Welz, Julia; Frenel, Jean-Sébastien; Leary, Alexandra
卵巢癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏